Inessa BioSoothe

Inessa BioSoothe

Regular price £38.99

WHAT IS INESSA BIOSOOTHE?

BioSoothe is a unique combination of nutrients and plant extracts shown to exert anti-inflammatory effects in the human body. The ingredients have all been shown to scientifically modulate or impact the many inflammatory pathways that exist in the body. Our ingredients have been combined in clinically relevant doses and in highly absorbable nutrient forms to create a highly potent, science-led, and effective anti-inflammatory complex. It is suitable for any situation where excess inflammation may be an issue. BioSoothe works well combined with the anti-inflammatory effects of Omega 3, and in some cases a probiotic supplement.

Works well with...

BioSoothe works well combined with the anti-inflammatory effects of Omega 3, and in some cases a probiotic supplement.

What does BioSoothe contain?

TWO CAPSULES TYPICALLY CONTAINS

Vitamin D 50mcg (2000iu)​ 1000% EU NRV*​
Zinc ​15mg​ 150% EU NRV*​
Liposomal turmeric​ 328mg
  providing Curcuminoids 210mg
Bromelain 312mg
Butyric acid​ 100mg
Resveratrol 100mg
Boswellia extract 100mg
  providing AKBA 20mg
Alpha lipoic acid 100mg
Quercetin 100mg
Ginger extract 60mg
  providing Gingerols 3mg

*NRV = Nutrient Reference Value

Ingredients

Liposomal turmeric extract (Soya), Bromelain, Delayed release capsule (Hydroxypropylmethylcellulose), Resveratrol, Alpha lipoic acid, Boswellia serrata extract, Quercetin, Sodium butyrate, Organic turmeric powder, Zinc picolinate, Ginger root extract, Bamboo silica, Vegan vitamin D3 (Cholecalciferol).

Sodium butyrate has a distinctive acidic smell which some may find unpleasant, however, we decided to include it as an ingredient as it has been shown to reduce gut inflammation and we feel its benefits outweigh any potential momentary discomfort when taking.


Evidence-based dose

How is BioSoothe different?

Other anti-inflammatory complexes only usually include a few of these anti-inflammatory nutrients, leading the consumer to have to purchase multiple products.

We include 9 active ingredients that influence at least one of the body’s processes for causing inflammation, so by combining a large number of ingredients - each of which acts on a separate inflammatory pathway - we have created a product that targets inflammation efficiently and effectively.


Delayed-release

Delayed-release

BioSoothe’s potent ingredients are packaged in delayed-release capsules. This is so that the ingredients reach the gut where they are released and can be most effective.


For daily use

Directions for use

Take 2 capsules per day with food. BioSoothe can be taken at any time of day but we recommend taking it in the morning just before breakfast.


Vegan Society approval pending

  1. Ng, Qin Xiang et al. “The role of inflammation in irritable bowel syndrome (IBS).” Journal of inflammation research vol. 11 345-349. 21 Sep. 2018, doi:10.2147/JIR.S174982
  2. Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Thabane M, Kottachchi DT, Marshall JK. Aliment Pharmacol Ther. 2007 Aug 15; 26(4):535-44.
  3. Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001 Apr 7;357(9262):1076-9. PubMed PMID:11297958.
  4. Pelucchi C, Chatenoud L, Turati F et al. Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: A meta-analysis. Epidemiology. 2012 May; 23(3):402-14.
  5. Armas LAG, Hollis BW and Heaney RP, 2004. Vitamin D2 is less effective than vitamin D3 in humans. Journal of Clinical Endocrinology & Metabolism, 89, 5387 – 5391.
  6. Tripkovic L, Lambert H, Hart K, Smith CP, Bucca G, Penson S, Chope G, Hypponen E, Berry J, Vieth R, Lanham-New S. Comparison of Vitamin D2 and Vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status; a systematic review and meta analysis. Am J Clin Nutr. 2012 Jun;95(6):1357-64.
  7. Overview of Zinc Absorption and Excretion in the Human Gastrointestinal Tract. Nancy F. Krebs The Journal of Nutrition, Volume 130, Issue 5, May 2000, Pages 1374S–1377S,
  8. Scientific Opinion on the substantiation of health claims related to vitamin D and normal​ function of the immune system and inflammatory response (ID 154, 159), maintenance of normal muscle. function (ID 155) and maintenance of normal cardiovascular function (ID 159) pursuant to Article 13(1) of Regulation (EC) No 1924/20061
  9. Yang, C. Y., Leung, P. S., Adamopoulos, I. E., & Gershwin, M. E. (2013). The implication of vitamin D and autoimmunity: a comprehensive review. Clinical reviews in allergy & immunology, 45(2), 217–226. doi:10.1007/s12016-013-8361-3
  10. Li J, Chen N, Wang D, Zhang J, Gong X. Efficacy of Vitamin D in treatment of inflammatory bowel disease: A met analysis. Medicine (Baltimore), 2018;(46):e12662.
  11. Heaton, L.E., Davis, J.K., Rawson, E.S. et al. Selected In-Season Nutritional Strategies to Enhance Recovery for Team Sport Athletes: A Practical Overview. Sports Med 47, 2201–2218 (2017) doi:10.1007/s40279-017-0759-2
  12. Scientific Opinion on the substantiation of health claims related to zinc and function of the immune system (ID 291, 1757), DNA synthesis and cell division (ID 292, 1759), protection of DNA, proteins and lipids from oxidative damage (ID 294, 1758), maintenance of bone (ID 295, 1756), cognitive function (ID 296), fertility and reproduction (ID 297, 300), reproductive development (ID 298), muscle function (ID 299), metabolism of fatty acids (ID 302), maintenance of joints (ID 305), function
  13. of the heart and blood vessels (ID 306), prostate function (ID 307), thyroid function (ID 308), acid-base metabolism (ID 360), vitamin A metabolism (ID 361) and maintenance of vision (ID 361) pursuant to Article 13(1) of Regulation (EC) No 1924/20061 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)2
  14. ​Bao, B., Prasad, A.S., Beck, F. W., Fitzgerald,J.T., Snell, D., Bao, G.W., Singh, T., and Cardozo, L.J. Zinc decreases C-reactive protein, lipid peroxidation, and inflammatory cytokines in elderly subjects: a potential implication of zinc as an atheroprotective agent. Am J Clin Nutr 2010;91(6):1634-1641.
  15. Prasad A. S. (2014). Zinc is an Antioxidant and Anti-Inflammatory Agent: Its Role in Human Health. Frontiers in nutrition, 1, 14. doi:10.3389/fnut.2014.00014
  16. ​Sjogren A, Floren CH, Nilsson A. Evaluation of zinc status in subjects with Crohn's disease. J Am Coll Nutr 1988;7:57-60.
  17. ​van de Wal Y, van der Sluys Veer A, Verspaget HW, et al. Effect of zinc therapy on natural killer cell activity in inflammatory bowel disease. Aliment Pharmacol Ther 1993;7:281-6.
  18. ​Dronfield MW, Malone JD, Langman MJ. Zinc in ulcerative colitis: a therapeutic trial and report on plasma levels. Gut 1977;18:33-6.
  19. Comparative absorption of zinc picolinate, zinc citrate and zinc gluconate in humans. Barrie SA, Wright JV, Pizzorno JE, Kutter E, Barron PC. PubMed 1987 Jun;21(1-2):223-8.
  20. Recent Developments in Delivery, Bioavailability, Absorption and Metabolism of Curcumin: the Golden Pigment from Golden Spice Sahdeo Prasad, PhD, Amit K. Tyagi, PhD, and Bharat B. Aggarwal, PhD, Cancer Res Treat. 2014 Jan; 46(1): 2–18.
  21. Marjan Daeihamed, Simin Dadashzadeh, Azadeh Haeri, Masoud Faghih Akhlaghi. Potential of Liposomes for Enhancement of Oral Drug Absorption Current Drug Delivery
  22. Bundy, R., Walker, A. F., Middleton, R. W., and Booth, J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern.Complement Med. 2004;10(6):1015-1018.
  23. ​Portincasa P, Bonfrate L, Scribano ML, et al. Curcumin and fennel essential oil improve symptoms and quality of life in patients with irritable bowel syndrome. J Gastrointestin Liver Dis. 2016 Jun;25(2):151-7
  24. Zhang F, Altorki NK, Metre JR, et al. Curcumin inhibits cycloxgenase-2 transcription in bile acid and phobol ester treated human gastrointestinal epithelial cells. Carcinogenesis 1999;20;445-51
  25. Surh YJ. Anti-tumor promoting potential of selected spice ingredients with antioxidative and anti-inflammatory activities: a short review. Food Chem Toxicol 2002;40:1091-7.
  26. Araujo CC, Leon LL. Biological activities of Curcuma longa L. Mem Inst Oswaldo Cruz 2001;96:723-8
  27. ​Akada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004;23:9247-58.
  28. Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res 2012;26:1719-25
  29. Lantz, R. C., Chen, G. J., Solyom, A. M., Jolad, S. D., and Timmermann, B. N. The effect of turmeric extracts on inflammatory mediator production. Phytomedicine. 2005;12(6-7):445-452.
  30. ​Huang, M. T., Lysz, T., Ferraro, T., Abidi, T. F., Laskin, J. D., and Conney, A. H. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res. 2-1-1991;51(3):813-819.
  31. ​Flynn, D. L., Rafferty, M. F., and Boctor, A. M. Inhibition of 5-hydroxy-eicosatetraenoic acid (5-HETE) formation in intact human neutrophils by naturally-occurring diarylheptanoids: inhibitory activities of curcuminoids and yakuchinones. Prostaglandins Leukot.Med. 1986;22(3):357-360.
  32. ​Hale LP, Greer PK, Sempowski GD. Bromelain treatment alters leukocyte expression of cell surface molecules involved in cellular adhesion and activation. Clin Immunol 2002;104:183-90.
  33. ​Klein, G., Kullich, W., Schnitker, J., and Schwann, H. Efficacy and tolerance of an oral enzyme combination in painful osteoarthritis of the hip. A double-blind, randomised study comparing oral enzymes with non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol. 2006;24(1):25-30.
  34. Izaka, K. I., Yamada, M., Kawano, T., and Suyama, T. Gastrointestinal absorption and antiinflammatory effect of bromelain. Jpn J Pharmacol 1972;22(4):519-534.
  35. ​Seligman B. Bromelain: an anti-inflammatory agent. Angiology 1962;13:508-510.
  36. Rathnavelu, V., Alitheen, N.B., Sohila, S., Kanagesan, S., & Ramesh, R. (2016). Potential role of bromelain in clinical and therapeutic applications (Review). Biomedical Reports, 5, 283-288. https://doi.org/10.3892/br.2016.720
  37. Brien, S., Lewith, G., Walker, A., Hicks, S. M., & Middleton, D. (2004). Bromelain as a Treatment for Osteoarthritis: a Review of Clinical Studies. Evidence-based complementary and alternative medicine : eCAM, 1(3), 251–257. doi:10.1093/ecam/neh035
  38. FEMS Microbiol Lett. 2002 Dec 17;217(2):133-9.The microbiology of butyrate formation in the human colon. Pryde SE1, Duncan SH, Hold GL, Stewart CS, Flint HJ.
  39. Prz Gastroenterol. 2013; 8(6): 350–353.Butyric acid in irritable bowel syndromeAndrzej Załęski,1 Aleksandra Banaszkiewicz,1 and Jarosław Walkowiak2
  40. Prz Gastroenterol. 2013;8(5):295-8. doi: 10.5114/pg.2013.38731. Epub 2013 Oct 28. Butyric acid in functional constipation. Pituch A1, Walkowiak J2, Banaszkiewicz A1.
  41. Aliment Pharmacol Ther. 2005 Nov 1;22(9):789-94. Oral butyrate for mildly to moderately active Crohn's disease. Di Sabatino A1, Morera R, Ciccocioppo R, Cazzola P, Gotti S, ​Tinozzi FP​, Tinozzi S, ​Corazza GR​.
  42. Assisi RF; GISDI Study Group. Combined butyric acid/mesalazine treatment in ulcerative colitis with mild-moderate activity. Results of a multicentre pilot study. Minerva Gastroenterol Dietol. 2008 Sep;54(3):231-8. PubMed PMID: 18614971.
  43. Zhang, M., Zhou, Q., Dorfman, R.G. et al. Butyrate inhibits interleukin-17 and generates Tregs to ameliorate colorectal colitis in rats. BMC Gastroenterol 16, 84 (2016)
  44. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275:218-20.
  45. ​Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004;23:9247-58.
  46. Murias M, Handler N, Erker T, et al. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem 2004;12:5571-8
  47. Kimura, Y., Okuda, H., and Kubo, M. Effects of stilbenes isolated from medicinal plants on arachidonate metabolism and degranulation in human polymorphonuclear leukocytes. J Ethnopharmacol. 1995;45(2):131-139
  48. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene. 2004 Dec 9;23(57):9247-58. PubMed PMID: 15489888.
  49. Abdel-Tawab, M., Werz, O. & Schubert-Zsilavecz, M. Boswellia serrata. Clin Pharmacokinet 50, 349–369 (2011).
  50. Kimmatkar N, Thawani V, Hingorani L, Khiyani R. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee--a randomized double blind placebo controlled trial. Phytomedicine. 2003 Jan;10(1):3-7. PubMed PMID: 12622457.
  51. Gupta I, Gupta V, Parihar A, Gupta S, Lüdtke R, Safayhi H, Ammon HP. Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of adouble-blind, placebo-controlled, 6-week clinical study. Eur J Med Res. 1998 Nov 17;3(11):511-4. PubMed PMID: 9810030.
  52. Gupta I, Parihar A, Malhotra P, et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 1997;2:37-43.
  53. Gupta I, Parihar A, Malhotra P, et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 2001;67:391-5.
  54. ​Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R. [Therapy of active Crohn disease with Boswellia serrata extract H 15]. Z Gastroenterol. 2001 Jan;39(1):11-7. German. PubMed PMID: 11215357.
  55. Triantafyllidi, Aikaterini et al. “Herbal and plant therapy in patients with inflammatory bowel disease.” Annals of gastroenterology vol. 28,2 (2015): 210-220.
  56. Ammon, H. P. [Boswellic acids (components of frankincense) as the active principle in treatment of chronic inflammatory diseases]. Wien.Med Wochenschr. 2002;152(15-16):373-378
  57. Safayhi, H., Mack, T., Sabieraj, J., Anazodo, M. I., Subramanian, L. R., and Ammon, H. P. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol.Exp.Ther 1992;261(3):1143-1146.
  58. Ammon, H. P., Mack, T., Singh, G. B., and Safayhi, H. Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of Boswellia serrata. Planta Med 1991;57(3):203-207.
  59. Safayhi, H., Sailer, E. R., and Ammon, H. P. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol.Pharmacol. 1995;47(6):1212-1216
  60. ER S​ailer, E. R., Subramanian, L. R., Rall, B., Hoernlein, R. F., Ammon, H. P., and Safayhi, H. Acetyl-11-keto-beta-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity. Br.J Pharmacol. 1996;117(4):615-618.
  61. Zhang Y., Han P., Wu N., He B., Lu Y., Li S., Liu Y., Zhao S., Liu L., Li Y. Amelioration of lipid abnormalities by a-lipoic acid through antioxidative and anti-inflammatory effects. Obesity (Silver Spring) 2011;19(8):1647-1653.
  62. Khabbazi T., Mahdavi R., Safa J., Pour-Abdollahi P. Effects of alpha-lipoic acid supplementation on inflammation, oxidative stress, and serum lipid profile levels in patients with end-stage renal disease on hemodialysis. J Ren Nutr 2012;22(2):244-250
  63. Sola, S., Mir, M. Q., Cheema, F. A., Khan-Merchant, N., Menon, R. G., Parthasarathy, S., and Khan, B. V. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 1-25-2005;111(3):343-348
  64. Carullo G, Cappello AR, Frattaruolo L, Badolato M, Armentano B, Aiello F. Quercetin and derivatives: useful tools in inflammation and pain management. Future Med Chem. 2017 Jan;9(1):79-93.
  65. Comalada, M., Camuesco, D., Sierra, S., Ballester, I., Xaus, J., Gálvez, J. and Zarzuelo, A. (2005), ​In vivoq​ uercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-κB pathway. Eur. J. Immunol., 35: 584-592.
  66. White, Martha (1999). ​"Mediators of inflammation and the inflammatory process"​. The Journal of Allergy and Clinical Immunology. 103. Retrieved 8 June 2019.
  67. Ojewole JA. Analgesic, antiinflammatory and hypoglycaemic effects of ethanol extract of Zingiber officinale (Roscoe) rhizomes (Zingiberaceae) in mice and rats. Phytother Res. 2006;20:764-72
  68. Jung, H. W., Yoon, C. H., Park, K. M., Han, H. S., and Park, Y. K. Hexane fraction of Zingiberis Rhizoma Crudus extract inhibits the production of nitric oxide and proinflammatory cytokines in LPS-stimulated BV2 microglial cells via the NF-kappaB pathway. Food Chem.Toxicol. 2009;47(6):1190-1197.
  69. Frondoza CG, Sohrabi A, Polotsky A, et al. An in vitro screening assay for inhibitors of proinflammatory mediators in herbal extracts using human synoviocyte cultures. In Vitro Cell Dev Biol Anim 2004;40:95-101.
  70. Phan, P. V., Sohrabi, A., Polotsky, A., Hungerford, D. S., Lindmark, L., and Frondoza, C. G. Ginger extract components suppress induction of chemokine expression in human synoviocytes. J Altern.Complement Med 2005;11(1):149-154.
  71. Jung, H. W., Yoon, C. H., Park, K. M., Han, H. S., and Park, Y. K. Hexane fraction of Zingiberis Rhizoma Crudus extract inhibits the production of nitric oxide and proinflammatory cytokines in LPS-stimulated BV2 microglial cells via the NF-kappaB pathway. Food Chem.Toxicol. 2009;47(6):1190-1197
  72. Lee, T. Y., Lee, K. C., Chen, S. Y., and Chang, H. H. 6-Gingerol inhibits ROS and iNOS through the suppression of PKC-alpha and NF-kappaB pathways in lipopolysaccharide-stimulated mouse macrophages. Biochem.Biophys.Res Commun. 4-24-2009;382(1):134-139.
  73. Zick, S. M., Turgeon, D. K., Vareed, S. K., Ruffin, M. T., Litzinger, A. J., Wright, B. D., Alrawi, S., Normolle, D. P., Djuric, Z., and Brenner, D. E. Phase II study of the effects of ginger root extract on eicosanoids in colon mucosa in people at normal risk for colorectal cancer. Cancer Prev.Res.(Phila) 2011;4(11):1929-1937.
  74. Drozdov VN, Kim VA, Tkachenko EV, Varvanina GG. Influence of a specific ginger combination on gastropathy conditions in patients with osteoarthritis of the knee or hip. J Alt Compl Med 2012;18:583-8.